Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/news/latest/ADC-Therapeutics-Doses-First-Patient-in-Phase-Ib-Clinical-Trial-of-ADCT-301-in-Patients-with-Advan-27821001/?utm_source=whatsapp&utm_medium=social&utm_campaign=share